Thus, the potency (e.g. IC50) and selectivity (e.g. TBK1-selective versus TBK1/IKKe dual) should be considered when choosing which TBK1 inhibitors to pursue in clinical trials for cancer therapy. Here, IKBKE is linked to cancer.